Novo Nordisk aims to launch more than five blockbuster drugs by 2030: CEO
The company is racing to reassure markets that it can navigate patent expirations for semaglutide - the active ingredient in its anti-obesity drugs Ozempic and Wegovy franchises, in the early 2030s
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.business-standard.com — the content belongs to Business Standard.
